Suppr超能文献

通过无细胞环介导等温扩增(CF-LAMP)进行非侵入性 EGFR 突变检测。

Non-invasive detection of EGFR mutations by cell-free loop-mediated isothermal amplification (CF-LAMP).

机构信息

Division of Molecular Genetics and Cancer, Nitte University Centre for Science Education and Research (NUCSER), Nitte (Deemed to be University), Kotekar-Beeri Road, Deralakatte, Mangaluru, 575018, India.

Department of Pulmonary Medicine, K S Hegde Medical Academy, Nitte (Deemed to be University), Mangaluru, 575018, India.

出版信息

Sci Rep. 2020 Oct 16;10(1):17559. doi: 10.1038/s41598-020-74689-3.

Abstract

Targeting epidermal growth factor receptor (EGFR) through tyrosine kinase inhibitors (TKI) is a successful therapeutic strategy in non-small cell lung cancer. However, the response to TKI therapy depends on specific activating and acquired mutations in the tyrosine kinase domain of the EGFR gene. Therefore, confirming the EGFR status of patients is crucial, not only for determining the eligibility, but also for monitoring the emergence of mutations in patients under TKI therapy. In this study, our aim was to develop a cost effective, yet sensitive, technique that allows the detection of therapeutically-relevant EGFR hotspot mutations at isothermal conditions in a non-invasive manner. Previously, we developed an allele-specific loop-mediated isothermal amplification (AS-LAMP) assay for screening germline and somatic de novo T790M EGFR mutation in lung cancer patients. In this study, we used cell free DNA as a template in AS-LAMP assay (CF-LAMP) for non-invasive detection of two hotspot EGFR mutations (T790M, and L858R) and compared its efficiency with ultrasensitive droplet digital PCR (ddPCR) assay. The results of CF-LAMP assay were consistent with those obtained in ddPCR assay, indicating the robustness of the method. CF-LAMP may serve as a valuable and cost-effective alternative for liquid biopsy techniques used in molecular diagnosis of non-small cell lung cancer.

摘要

针对表皮生长因子受体(EGFR)的酪氨酸激酶抑制剂(TKI)是治疗非小细胞肺癌的一种成功策略。然而,TKI 治疗的反应取决于 EGFR 基因酪氨酸激酶结构域的特定激活和获得性突变。因此,确定患者的 EGFR 状态至关重要,不仅要确定其是否符合治疗条件,还要监测 TKI 治疗患者的突变情况。在这项研究中,我们旨在开发一种具有成本效益但又敏感的技术,以便在非侵入性条件下在等温条件下检测治疗相关的 EGFR 热点突变。之前,我们开发了一种用于筛选肺癌患者种系和体细胞新出现的 T790M EGFR 突变的等位基因特异性环介导等温扩增(AS-LAMP)检测法。在这项研究中,我们使用无细胞 DNA 作为模板进行 AS-LAMP 检测(CF-LAMP),以非侵入性方式检测两种热点 EGFR 突变(T790M 和 L858R),并将其效率与超敏度的液滴数字 PCR(ddPCR)检测法进行比较。CF-LAMP 检测的结果与 ddPCR 检测法一致,表明该方法具有稳健性。CF-LAMP 可作为非小细胞肺癌分子诊断中用于液体活检技术的一种有价值且具有成本效益的替代方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d63/7568567/c047ad51ddc1/41598_2020_74689_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验